7427.TWO Great Novel Therapeutics Biotech & Medicals

Healthcare Biotechnology Taiwan OTC Exchange
58.20 TWD
Close of Nov 6, 2026
29.25 82.80
Market cap
TWD 3.08B
P/E
-
P/B
4.30x
ROE
-19.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7427.TWO undervalued?

Graham number

The Graham number of Great Novel Therapeutics Biotech & Medicals cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Great Novel Therapeutics Biotech & Medicals fundamental analysis

No fundamental analysis for Great Novel Therapeutics Biotech & Medicals yet.

Great Novel Therapeutics Biotech & Medicals stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Great Novel Therapeutics Biotech & Medicals

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. I…

Full company profile